Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 6Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1HRD Cancer 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Brain Neoplasms 1

Interventions

atezolizumab 4Nivolumab 4Cisplatin 4Topotecan 2Radiosurgery 2Paclitaxel 2Ipilimumab 2Immunoglobulin G 2Etoposide 2Disulfides 2veliparib 1tocilizumab 1repotrectinib 1pralsetinib 1pembrolizumab 1niraparib 1iadademstat 1durvalumab 1dostarlimab 1cabozantinib 1budigalimab 1berzosertib 1belinostat 1Temozolomide 1Specimen Handling 1Radiotherapy 1Podophyllotoxin 1Platinum 1Magnetic Resonance Spectroscopy 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × berzosertib × Thoracic × Clear all
NCT02487095 2025-04-13

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
62 enrolled 29 charts
EndocrineGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡